Literatur
-
1
Geisthövel F.
Funktioneller Hyperandrogenismus (sog. „Syndrom polyzystischer Ovarien“).
Gynäkologe.
2002;
35
48-63
-
2
Fassnacht M, Schlenz N, Schneider S B, Wudy S A, Allolio B, Arlt W.
Beyond adrenal and ovarian androgen generation: Increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome.
J Clin Endocrinol Metab.
2003;
88
2760-2766
-
3
Speiser P W, White P C.
Congenital adrenal hyperplasia.
N Engl J Med.
2003;
349
776-788
-
4
Dörr H G, Sippell W G.
Prenatal dexamethasone treatment in pregnancies at risk for congenital adrenal hyperplasia due to 21-hydroxylase deficiency: effect on midgestational amniotic fluid steroid levels.
J Clin Endocrinol Metab.
1993;
76
117-120
-
5
Joint LWPES/ESPE CAH Working Group .
Consensus Statement on 21-Hydroxylase Deficiency from The Lawson Wilkins Pediatric Endocrine Society and The European Society for Paediatric Endocrinology.
J Clin Endocrinol Metab.
2002;
87
4048-4053
-
6
New M I, Carlson A, Obeid J. et al .
Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies.
J Clin Endocrinol Metab.
2001;
86
5661-5667
-
7
Meyer-Bahlburg H F, Dolezahl C, Baker S W, Carlson D, New M I.
Cognitive and motor development of children with and without congenital adrenal hyperplasia after early-prenatal dexamethasone.
J Clin Endocrinol Metab.
2004;
89
610-614
-
8 Zawadski J K, Dunaif A. Diagnostic criteria for polycystic ovarian syndrome: towards a rationale approach. Dunaif A, Givens JR, Haseltine F Polycystic Ovary Syndrome. (1st ed). Boston; Blackwell Scientific 1992: 377-384
-
9
Pierroz D D, Aebi A C, Huhtaniemi I T, Aubert M L.
Many LH peaks are needed to physiologically stimulate testosterone secretion: modulation by fasting and NPY.
Am J Physiol.
1999;
276
E603-E610
-
10
Hileman S M, Lubbers L S, Kuehl D E, Schaeffer D J, Rhodes L, Jackson G L.
Effect of inhibiting 5 alpha-reductase activity on the ability of testosterone to inhibit luteinizing hormone release in male sheep.
Biol Reprod.
1994;
50
1244-1250
-
11
Belgorosky A, Chahin S, Rivarola M A.
Elevation of serum luteinizing hormone levels during hydrocortisone treatment in infant girls with 21-hydroxylase deficiency.
Acta Paediatr.
1996;
85
1172-1175
-
12
Patel K, Coffler M S, Dahan M H. et al .
Increased luteinizing hormone secretion in women with polycystic ovary syndrome is unaltered by prolonged insulin infusion.
J Clin Endocrinol Metab.
2003;
88
5456-5461
-
13
Weiss J M, Polack S, Diedrich K, Ortmann O.
Effects of insulin on luteinizing hormone and prolactin secretion and calcium signaling in female rat pituitary cells.
Arch Gynecol Obstet.
2003;
269
45-50
-
14
Adams J, Frank S, Polson D W, Abdulwahid N. et al .
Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone.
Lancet.
1985;
2
1375-1379
-
15
Revised consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.
Fertil Steril.
2004;
81
19-25
-
16
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).
Hum Reprod.
2004;
19
41-47
-
17
Nahum R, Thong K J, Hillier S G.
Metabolic regulation of androgen production by human thecal cells in vitro.
Hum Reprod.
1995;
10
75-81
-
18
Dunaif A.
Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.
Endocr Rev.
1997;
18
774-800
-
19
Poretsky L, Kalin M F.
The gonadotropic function of insulin.
Endocr Rev.
1987;
8
132-141
-
20
Xia Y X, Weiss J M, Polack S, Diedrich K, Ortmann O.
Interactions of insulin-like growth factor-I, insulin and estradiol with GnRH-stimulated luteinizing hormone release from female rat gonadotrophs.
Eur J Endocrinol.
2001;
144
73-79
-
21
King H, Rewers M.
Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. WHO Ad Hoc Diabetes Reporting Group.
Diabetes Care.
1993;
16
157-177
-
22
Ehrmann D A, Barnes R B, Rosenfield R L, Cavaghan M K, Imperial J.
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Diabetes Care.
1999;
22
141-146
-
23
Legro R S, Kunselman A R, Dodson W C, Dunaif A.
Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.
J Clin Endocrinol Metab.
1999;
84
165-169
-
24
Norman R J, Masters L, Milner C R, Wang J X, Davies M J.
Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.
Hum Reprod.
2001;
16
1995-1998
-
25
Peppard H R, Marfori J, Iuorno M J, Nestler J E.
Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes.
Diabetes Care.
2001;
24
1050-1052
-
26
Conn J J, Jacobs H S, Conway G S.
The prevalence of polycystic ovaries in women with type 2 diabetes mellitus.
Clin Endocrinol (Oxf).
2000;
52
81-86
-
27
Solomon C G, Hu F B, Dunaif A. et al .
Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus.
Jama.
2001;
286
2421-2426
-
28
Colilla S, Cox N J, Ehrmann D A.
Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives.
J Clin Endocrinol Metab.
2001;
86
2027-2031
-
29
Dunaif A, Segal K R, Futterweit W, Dobrjansky A.
Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome.
Diabetes.
1989;
38
1165-1174
-
30
Dunaif A, Segal K R, Shelley D R, Green G, Dobrjansky A, Licholai T.
Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome.
Diabetes.
1992;
41
1257-1266
-
31
Dunaif A, Xia J, Book C B, Schenker E, Tang Z.
Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome.
J Clin Invest.
1995;
96
801-810
-
32
Dunaif A, Finegood D T.
Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome.
J Clin Endocrinol Metab.
1996;
81
942-947
-
33
Ehrmann D A, Sturis J, Byrne M M, Karrison T, Rosenfield R L, Polonsky K S.
Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus.
J Clin Invest.
1995;
96
520-527
-
34
O'Meara N M, Blackman J D, Ehrmann D A. et al .
Defects in beta-cell function in functional ovarian hyperandrogenism.
J Clin Endocrinol Metab.
1993;
76
1241-1247
-
35
Book C B, Dunaif A.
Selective insulin resistance in the polycystic ovary syndrome.
J Clin Endocrinol Metab.
1999;
84
3110-3116
-
36
Bjercke S, Dale P O, Tanbo T, Storeng R, Ertzeid G, Abyholm T.
Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome.
Gynecol Obstet Invest.
2002;
54
94-98
-
37
Kannel W B, D'Agostino R B, Wilson P W, Belanger A J, Gagnon D R.
Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience.
Am Heart J.
1990;
120
672-676
-
38
Wild R A.
Obesity, lipids, cardiovascular risk, and androgen excess.
Am J Med.
1995;
98
27S-32S
-
39
Wild S, Pierpoint T, McKeigue P, Jacobs H.
Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study.
Clin Endocrinol (Oxf).
2000;
52
595-600
-
40
Amowitz L L, Sobel B E.
Cardiovascular consequences of polycystic ovary syndrome.
Endocrinol Metab Clin North Am.
1999;
28
439-458
viii
-
41
Birdsall M A, Farquhar C M, White H D.
Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization.
Ann Intern Med.
1997;
126
32-35
-
42
Paradisi G, Steinberg H O, Hempfling A. et al .
Polycystic ovary syndrome is associated with endothelial dysfunction.
Circulation.
2001;
103
1410-1415
-
43
Talbott E, Guzick D, Clerici A. et al .
Coronary heart disease risk factors in women with polycystic ovary syndrome.
Arterioscler Thromb Vasc Biol.
1995;
15
821-826
-
44
Talbott E O, Guzick D S, Sutton-Tyrrell K. et al .
Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women.
Arterioscler Thromb Vasc Biol.
2000;
20
2414-2421
-
45
Pierpoint T, McKeigue P M, Isaacs A J, Wild S H, Jacobs H S.
Mortality of women with polycystic ovary syndrome at long-term follow-up.
J Clin Epidemiol.
1998;
51
581-586
-
46
Solomon C G, Hu F B, Dunaif A. et al .
Menstrual cycle irregularity and risk for future cardiovascular disease.
J Clin Endocrinol Metab.
2002;
87
2013-2017
-
47
Hiort O, Holterhus P M, Nitsche E M.
Physiology and pathophysiology of androgen action.
Baillieres Clin Endocrinol Metab.
1998;
12
115-132
-
48
Diamanti-Kandarakis E, Baillargeon J P, Iuorno M J, Jakubowicz D J, Nestler J E.
A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills.
J Clin Endocrinol Metab.
2003;
88
1927-1932
-
49
Hammerstein J, Meckies J, Leo-Rossberg I, Moltz L, Zielske F.
Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism.
J Steroid Biochem.
1975;
6
827-836
-
50
Leo-Rossberg I, Laur S, Zielske F, Hammerstein J.
Reversed sequential therapy of hirsutism using cyproterone acetate. I. Further clinical observations.
Acta Endocrinol Suppl (Copenh).
1971;
152
14
-
51
Zielske F, Dreykluft R, Magnus U, Hammerstein J.
Reversed sequential therapy of hirsutism using cyproterone acetate. II. Hormonal analyses.
Acta Endocrinol Suppl (Copenh).
1971;
152
15
-
52
Azziz R, Black V Y, Knochenhauer E S, Hines G A, Boots L R.
Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
J Clin Endocrinol Metab.
1999;
84
946-950
-
53
Imani B, Eijkemans M J, Te Velde E R, Habbema J D, Fauser B C.
Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility.
J Clin Endocrinol Metab.
1999;
84
1617-1622
-
54
Eijkemans M J, Imani B, Mulders A G, Habbema J D, Fauser B C.
High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2).
Hum Reprod.
2003;
18
2357-2362
-
55
van Santbrink E J, Fauser B C.
Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistant anovulatory infertility: prospective, randomized comparison between low dose step-up and step-down dose regimens.
J Clin Endocrinol Metab.
1997;
82
3597-3602
-
56
van Santbrink E J, Donderwinkel P F, van Dessel T J, Fauser B C.
Gonadotrophin induction of ovulation using a step-down dose regimen: single-centre clinical experience in 82 patients.
Hum Reprod.
1995;
10
1048-1053
-
57
Venturoli S, Marescalchi O, Colombo F M. et al .
A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism.
J Clin Endocrinol Metab.
1999;
84
1304-1310
-
58
Carmina E, Lobo R A.
Treatment of hyperandrogenic alopecia in women.
Fertil Steril.
2003;
79
91-95
-
59
Carmina E, Lobo R A.
A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women.
Clin Endocrinol (Oxf).
2002;
57
231-234
-
60
Muderris I I, Bayram F, Guven M.
A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism.
Fertil Steril.
2000;
73
984-987
-
61
Fruzzetti F, Bersi C, Parrini D, Ricci C, Genazzani A R.
Treatment of hirsutism: comparisons between different antiandrogens with central and peripheral effects.
Fertil Steril.
1999;
71
445-451
-
62
Salpeter S R, Greyber E, Pasternak G A, Salpeter E E.
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis.
Arch Intern Med.
2003;
163
2594-2602
-
63
Haas D A, Carr B R, Attia G R.
Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome.
Fertil Steril.
2003;
79
469-481
-
64
Costello M F, Eden J A.
A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome.
Fertil Steril.
2003;
79
1-13
-
65
Harborne L, Fleming R, Lyall H, Sattar N, Norman J.
Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome.
J Clin Endocrinol Metab.
2003;
88
4116-4123
-
66
Lord J M, Flight I H, Norman R J.
Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.
Cochrane Database Syst Rev.
2003;
CD003053
-
67
Coetzee E J, Jackson W P.
Pregnancy in established non-insulin-dependent diabetics. A five-and-a-half year study at Groote Schuur Hospital. S. Afr.
Med J.
1980;
58
795-802
-
68
Coetzee E J, Jackson W P.
Diabetes newly diagnosed during pregnancy: A 4-year study at Groote Schuur Hospital.
S Afr Med J.
1979;
56
467-475
-
69
Jakubowicz D J, Iuorno M J, Jakubowicz S, Roberts K A, Nestler J E.
Effects of metformin on early pregnancy loss in the polycystic ovary syndrome.
J Clin Endocrinol Metab.
2002;
87
524-529
-
70
Vandermolen D T, Ratts V S, Evans W S, Stovall D W, Kauma S W, Nestler J E.
Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone.
Fertil Steril.
2001;
75
310-315
-
71
Glueck C J, Wang P, Goldenberg N, Sieve-Smith L.
Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin.
Hum Reprod.
2002;
17
2858-2864
-
72
Glueck C J, Wang P, Kobayashi S, Phillips H, Sieve-Smith L.
Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome.
Fertil Steril.
2002;
77
520-525
-
73
Glueck C J, Phillips H, Cameron D, Sieve-Smith L, Wang P.
Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study.
Fertil Steril.
2001;
75
46-52
-
74
Cavaghan M K, Ehrmann D A, Byrne M M, Polonsky K S.
Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.
J Clin Invest.
1997;
100
530-537
-
75
Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R.
The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.
J Clin Endocrinol Metab.
1996;
81
3299-3306
-
76
Ehrmann D A, Schneider D J, Sobel B E. et al .
Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.
J Clin Endocrinol Metab.
1997;
82
2108-2116
-
77
Azziz R, Ehrmann D, Legro R S. et al .
Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.
J Clin Endocrinol Metab.
2001;
86
1626-1632
-
78
Cataldo N A, Abbasi F, McLaughlin T L, Lamendola C, Reaven G M.
Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone.
Fertil Steril.
2001;
76
1057-1059
-
79
Ghazeeri G, Kutteh W H, Bryer-Ash M, Haas D, Ke R W.
Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome.
Fertil Steril.
2003;
79
562-566
-
80
Shobokshi A, Shaarawy M.
Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy.
J Soc Gynecol Investig.
2003;
10
99-104
-
81
Glueck C J, Moreira A, Goldenberg N, Sieve L, Wang P.
Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin.
Hum Reprod.
2003;
18
1618-1625
-
82
Nestler J E, Stovall D, Akhter N, Iuorno M J, Jakubowicz D J.
Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome.
Fertil Steril.
2002;
77
209-215
-
83
Crave J C, Fimbel S, LeJeune H, Cugnardey N, Dechaud H, Pugeat M.
Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women.
J Clin Endocrinol Metab.
1995;
80
2057-62
-
84
Nestler J E, Jakubowicz D J.
Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.
N Engl J Med.
1996;
335
617-623
-
85
Nestler J E, Jakubowicz D J.
Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens.
J Clin Endocrinol Metab.
1997;
82
4075-4079
-
86
Velazquez E, Acosta A, Mendoza S G.
Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.
Obstet Gynecol.
1997;
90
392-395
-
87
Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A.
Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome.
Eur J Endocrinol.
1998;
138
269-274
-
88
Morin-Papunen L C, Koivunen R M, Ruokonen A, Martikainen H K.
Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.
Fertil Steril.
1998;
69
691-696
-
89
Nestler J E, Jakubowicz D J, Evans W S, Pasquali R.
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
N Engl J Med.
1998;
338
1876-1880
-
90
Glueck C J, Wang P, Fontaine R, Tracy T, Sieve-Smith L.
Metformin-induced resumption of normal menses in 39 of 43 (91 %) previously amenorrheic women with the polycystic ovary syndrome.
Metabolism.
1999;
48
511-519
-
91
La Marca A, Morgante G, Paglia T, Ciotta L, Cianci A, De L V.
Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome.
Fertil Steril.
1999;
72
985-989
-
92
Pirwany I R, Yates R W, Cameron I T, Fleming R.
Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea.
Hum Reprod.
1999;
14
2963-2968
-
93
Unluhizarci K, Kelestimur F, Bayram F, Sahin Y, Tutus A.
The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.
Clin Endocrinol (Oxf).
1999;
51
231-236
-
94
Moghetti P, Castello R, Negri C. et al .
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
J Clin Endocrinol Metab.
2000;
85
139-146
-
95
Kolodziejczyk B, Duleba A J, Spaczynski R Z, Pawelczyk L.
Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.
Fertil Steril.
2000;
73
1149-1154
-
96
Pasquali R, Gambineri A, Biscotti D. et al .
Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
J Clin Endocrinol Metab.
2000;
85
2767-2774
-
97
Ibanez L, Valls C, Ferrer A, Marcos M V, Rodriguez-Hierro F, de Zegher F.
Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism.
J Clin Endocrinol Metab.
2001;
86
3595-3598
-
98
Baysal B, Batukan M, Batukan C.
Biochemical and body weight changes with metformin in polycystic ovary syndrome.
Clin Exp Obstet Gynecol.
2001;
28
212-214
-
99
Vrbikova J, Hill M, Starka L, Vondra K.
Prediction of the effect of metformin treatment in patients with polycystic ovary syndrome.
Gynecol Obstet Invest.
2002;
53
100-104
-
100
Fleming R, Hopkinson Z E, Wallace A M, Greer I A, Sattar N.
Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial.
J Clin Endocrinol Metab.
2002;
87
569-574
-
101
Karck U.
Therapie der Hyperandrogenämie und ihrer Symptome Hirsutismus, Seborrhö und Akne.
Gynäkologe.
2002;
35
22-30
-
102
Azziz R.
The evaluation and management of hirsutism.
Obstetrics & Gynecology.
2003;
101
995-1007
-
103
Lucky A W, Piacquadio D J, Ditre C M. et al .
A randomized, placebo-controlled trial of 5 % and 2 % topical minoxidil solutions in the treatment of female pattern hair loss.
J Am Acad Dermatol.
2004;
50
541-553
-
104
Bouhanna P.
Androgenetic alopecia: Combining medical and surgical treatments.
Dermatol Surg.
2003;
29)
1130-1134
-
105
Chen W C, Thiboutot D, Zouboulis C C.
Cutaneous androgen metabolism: Basic research and clinical perspectives.
J Invest Dermatol.
2002;
119
992-1007
-
106
Hanneken S, Ritzmann A, Nöthen M M, Kruse R.
Androgenetische Alopezie.
Hautarzt.
2003;
54
703-712
-
107
Hunter M H, Carek P J.
Evaluation and treatment of hirsutism.
American Family Physician.
2003;
67
2565-2572
-
108
Price V H.
Androgenetic alopecia in women.
J Invest Dermatol Symposium Proceedings.
2003;
8
24-27
-
109
Kaufmann K D.
Androgens and alopecia.
Mol Cell Endocrinol.
2002;
198
89-95
-
110 Van der Spuy Z M, le Roux P A. Cyproterone acetate for hirsutism. (Cochrane Review). The Cochrane Library. Chichester, UK; John Wiley & Sons, Ltd. 2004 2: 1-53
-
111 Farquar C, Lee O, Toomath R, Jepson R. Spironolactone versus placebo or in combination with steroids for Hirsutism and/or acne. (Cochrane Review). The Cochrane Library. Chichester, UK; John Wiley & Sons, Ltd. 2004 2: 1-33
-
112
Lumchi F, Rondinone R.
Use of cyproterone acetate, finasteride and spironolactone to treat idiopathic hirsurtism.
Fertil Steril.
2003;
79
942-946
-
113
Birch M P, Lalla S C, Messenger A G.
Female pattern hair loss.
Clin Dermatol.
2002;
27
283-388
-
114
Fischer T W, Burmeister G, Schmidt H W, Elsner P.
Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial.
Br J Dermatol.
2004;
150
341-345
-
115
Raulin C, Greve B.
Aktueller Stand der Photoepilation.
Hautarzt.
2000;
51
809-817
-
116
Trüeb R M.
Neues und Bewährtes in der Therapie von Haarerkrankungen.
Hautarzt.
2003;
45
732-740
-
117
McPhaul M J.
Factors that mediate and modulate androgen action.
J Invest Dermatol Symposium Proceedings.
2003;
8
1-5
-
118
Norwood O T.
Incidence of female androgenetic alopecia (female pattern alopecia).
Dermatol Surg.
2001;
27
53-54
-
119
Javidnia K, Dastgheib L, Samani M S, Nasiri A.
Antihirsutim activity of fennel (fruits of Foeniculum vulgare) extract. A double-blind placebo controlled study.
Phytomedicine.
2003;
10
455-458
-
120
Glueck C J, Goldenberg N, Wang P, Loftspring M, Sherman A.
Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy.
Hum Reprod.
2004;
19
510-521
-
121
Elder A T, Hague W M, Davoren P M, Oliver J. et al .
Contraindications to use of metformin.
BMJ.
2003;
326
762
-
122 National Collaborating Centre for Women's and Children's Health .Clinical Guideline. London; RCOG Press 2004: 1-216
-
123
Kunte C, Wolf H.
Aktuelle Therapie der Hypertrichosen.
Hautarzt.
2001;
52
993-997
-
124 Wolf H. unveröffentlichte Daten, LMU München. 2004
-
125 Farquhar C, Vandekerckhove P, Lilford R. Laparoscopic “drilling” by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. The Cochrane Library. Oxford; Update Software 2002 3
-
126
El Saeed M, Ezzar M, Hasan M, Elhelw Aboumaaty B Z, Aboulghar M.
High incidence of pelviv adhesions detected by secondary look laparoscopy after laparoscopic drilling.
Middle East Fert Soc J.
2000;
5
519-525
-
127
Farquhar C M, Williamson K, Brown P M, Garland J.
An economic evaluation of laparoscopic ovarian diathermy versus gonadotrophin therapy for women with clomiphene citrate resistant polycystic ovary syndrome.
Hum Reprod.
2004;
19
1110-1115
-
128
Shapiro L, Pastuszak A, Curto G, Koren G.
Safety of first trimester exposure to topical tretinoin (Letter).
Lancet.
1997;
350
1134-1144
-
129
Jick S S, Terris B Z, Jick H.
First trimester topical tretinoin and congenital disorders.
Lancet.
1993;
341
1181-1182
-
130 Thomas L. Labor und Diagnose. 5. Aufl. Frankfurt/Main; TH-Books 1998
Priv.-Doz. Dr. med. M. Ludwig
Endokrinologikum Hamburg
Zentrum für Hormon- und Stoffwechselerkrankungen, Reproduktionsmedizin und gynäkologische Endokrinologie
Lornsenstraße 6
22767 Hamburg
Phone: +49 (0) 40 3 06 28-320
Fax: +49 (0) 40 3 06 28-349
Email: Michael.Ludwig@Endokrinologikum.com
